Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Stopped Principal investigator leaving study site; no replacement PI will be sought

Conditions

• Melanoma (Skin)
• Melanoma Stage IIIb-IVM1a
• Metastasis Skin
• Tumor Skin
• BRAF Gene Mutation

Interventions

• DRUG: Talimogene laherparepvec (T-Vec)
• DRUG: Dabrafenib (BRAF Inhibitor)
• DRUG: Trametinib (MEK Inhibitor)

Sponsor

TriHealth Inc.

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]